关节炎
炎性关节炎
铅(地质)
类风湿性关节炎
医学
癌症研究
免疫学
生物
古生物学
作者
Chen-I Hsieh,Yu‐Hung Chen,Wen-Yi Tseng,Y. J. Jan,Yu‐Chun Huang,Chang‐Fu Kuo,Kena Yu,P.H. Tsai,S.-F. Luo
标识
DOI:10.1136/annrheumdis-2024-eular.2413
摘要
Background:
Fibroblast activation protein α (FAPα) is a cell surface serine protease expressed by activated fibroblasts, and it was found that FAP-deficiency mice have less cartilage degradation, inflammation, and bone erosion. Moreover, the fibroblast-like synoviocytes from rheumatoid arthritis patients have higher expression of FAPα in synovium tissue. Objectives:
We evaluated the ability of the 68Ga-labelled FAPI as a diagnostic method for RA diagnosis. We also investigated that 177Lu-labelled FAPI could lead to amelioration of RA by depletion of FAP+ FLS and subsequent inhibition of lymphocyte function. Methods:
The collagen-induced arthritis (CIA) DBA1/J mice were used as the inflammatory arthritis model. The images from 68Ga-FAPI-04 PET/CT examinations of CIA mice were analyzed, and the tracer uptakes would be quantified by the standardized uptake value (SUV) and compared with the disease score and incidence rate. Then 177Lu-labeled FAPI-04 was used to target FAPα-expressed cells in CIA mice as radiation therapy. Results:
The paws in CIA mice with higher SUV since 1 week after booster immunization had a higher incidence rate of arthritis. The SUV also correlated with arthritis scores because the expression of FAPα increased in CIA mice. Moreover, the 177Lu-labeled FAPI-04 treated group has a lower arthritis score compared with untreated CIA mice. Conclusion:
We provide the basic features of FAPα- expressed FLSs in RA pathophysiology and advances in targeted therapies. We present that Ga68-FAPI-04 can be a useful tracer for predicting arthritis, and targeting to FAPα- expressed FLSs may be a potential way for arthritis treatment. REFERENCES:
NIL. Acknowledgements:
This work was supported by grants from the Keelung Chang Gung Memorial Hospital, Taiwan, R.O.C. (CMRPG2K0172 and CMRPG2K0173) and NSTC-Granted Research Projects (NSTC 112-2314-B-182 -015 -MY3). Disclosure of Interests:
None declared.
科研通智能强力驱动
Strongly Powered by AbleSci AI